Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 12/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9196800 | 0.69 | ATM (0.43) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL3013753 | 0.68 | ROCK2 (0.47) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL8177314 | 0.68 | AGTR2 (0.49) | GBA1 | |
| SCHEMBL16687258 | 0.68 | DPP4 (0.43) | — | |
| SCHEMBL15094982 | 0.68 | SLC6A2 (0.46) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL5929231 | 0.68 | ATM (0.45) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL350911 | 0.67 | HSD11B1 (0.48) | ABHD6DAGLA | |
| SCHEMBL2606119 | 0.67 | ADRA2A (0.53) | — | |
| SCHEMBL27304337 | 0.67 | HSD11B1 (0.45) | ABHD6DAGLA | |
| SCHEMBL7413375 | 0.67 | HSD11B1 (0.45) | ABHD6DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108930-B2 | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140018318-A1 | N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS | THE SCIPPS RESEARCH INSTITUTE (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2012138877-A1 | N1- AND N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018318-A1 | N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS | PRSS1, PRSS3, CES1 | ROCK2 1834/4885ROCK1 891/4885CDC42BPB 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.